SARS-CoV-2 Variant Spike Protein Trimers

We have and will continue to develop high-quality recombinant purified SARS-CoV-2 trimers for all major variants to date. Check back here for updates as new variants emerge. Order directly or contact us for bulk pricing options.

SARS-CoV-2 Therapeutic mAb Development

Using our rabbit monoclonal antibody discovery platform RabWiz, we developed a potent mAb that showed strong neutralization of the Wuhan-Hu-1 strain. We humanized this antibody and subjected it to our proprietary STEM affinity maturation platform, iteratively improving affinity and broadening neutralization potency on SARS-CoV-2 variants as they emerged. This resulted in the most potent, broadest neutralizing COVID-19 therapeutic mAbs to date.

See our published work, detailing our engineering strategy and assaying antibody potency: Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.

Next-generation Quantitative COVID-19 Antigen Tests

We have developed high affinity, highly specific rabbit antibodies that can be used in antigen diagnostic tests for active SARS-CoV-2 infections. These antibodies target multiple epitopes within the nucleoprotein (NP) of SARS-CoV-2, allowing for sandwich immunoassay detection compatible with any existing antibody diagnostic methods. The epitopes are also unique to SARS-CoV-2 compared to related coronaviruses, allowing for highly specific detection. These antibodies are available from our catalog in unconjugated or biotinylated format. We are currently developing a lateral flow assay using these antibodies to create a rapid diagnostic test.

Here you can find our catalog of COVID-19 research reagents or our recommended pair of unconjugated and biotinylated antibodies for use in your own assays.


Abwiz mAbs show pM affinity to SARS-CoV-2 nucleocapsid protein (NP)